Branded vial and pen-kit presentation. Confirm the available format, contents and packaging for this product.
Tirzepatide
A dual GIP and GLP-1 receptor agonist for metabolic pathway research.
Listed content per unit- Presentation
- Vial presentation
- Local dispatch markets
- Australia · Canada · USA
- Availability
- Confirm by strength & location
- Documentation
- Request product & batch records
For qualified research enquiries. Listed content is not a dose or administration instruction.
The research context
Tirzepatide acts at the GIP and GLP-1 receptors. These incretin pathways are involved in glucose-dependent signalling, appetite and metabolism, making the molecule relevant to metabolic research.
Compare the receptor pathways in our metabolic peptide research guide, including GLP-1, GIP and glucagon signalling.
Tirzepatide is the active ingredient in specific approved prescription medicines, including Mounjaro and Zepbound. Those approvals do not apply to an Aurelis research vial.
What does Tirzepatide do?
Read our Tirzepatide guide for a simple explanation of weight loss, appetite and blood sugar and what studies found.
What to include in your enquiry
Tell us your required compound, strength, presentation and destination country. If you have a particular analytical requirement, include the method or document you need so the team can match your request to the relevant specification.
Selected scientific references
These sources describe published research or a specific regulated medicine. They are not certificates for an Aurelis batch.
Connect with Aurelis
Your next enquiry
starts with the details.
Tell us the compound, listed content, preferred presentation and destination. Our team can discuss local availability and the documentation for your selected material.